Media Release
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
MEDIA RELEASEEUR 50m investment in Kundl plant extension emp
Sandoz receives FDA approval for first and only denosumab biosimilars
MEDIA RELEASEWyost® (denosumab-bddz) and Jubbonti® (denosuma
Sandoz announces nominations to the Board of Directors and leadership change
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
MEDIA RELEASECIMERLI®*, a ranibizumab biosimilar, is interch
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
Sandoz announces changes in the Board of Directors
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L
【主編前言】換湯亦換藥
近兩年隨著疫後重開各口岸，博彩旅遊業復甦勢頭強勁，雖然仍未重回疫情前巔峰，但亦已回復七、八成，只是這種復甦只局限與博彩旅遊業相關的行業或地區，加上澳車北上政策吸引了大量澳門居民北上消費，一般民生區的店舖與旅遊區的店舖彷如處於平衡時空，旅遊區店舖生意有多旺，非旅遊區店舖生意有多差。
Mandy Kuok
【社長之言】我們不應安於現狀
“如何在經濟復甦過程中有效應對澳門本土經濟發展不充分、不平衡的問題？如何解決產業多元化發展與社會期待不符的問題？中小企業普遍面對且迫切的困難？在粵澳合作框架下，如何更好地利用橫琴的發展，讓其更有效地為澳門經濟發展作出貢獻？”
馬天龍